12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist by Quinn Deveraux, Heather Kinkead, Chelsie Macedo, Angelica Sanabria, Garrett Cyprus, Rajay Pandit, James Kalabus, Bryan Becklund, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt